Please login to the form below

Not currently logged in
Email:
Password:

Omeros phase III knee surgery drug fails

A Omeros Corporation drug developed to increase mobility and reduce pain in patients who have undergone arthroscopic knee surgery has failed to meet the primary endpoints of a phase III programme

Omeros Corporation's lead product candidate, a drug intended to increase mobility and reduce pain in patients who have undergone arthroscopic knee surgery, has failed to meet the primary endpoints of a phase III programme because of confounding factors that made it impossible to draw conclusions from the research, according to the company.

The drug was being evaluated in patients undergoing arthroscopic anterior cruciate ligament (ACL) reconstruction surgery, an indication for which no other pharmaceuticals are approved in the US. Currently known as OMS103HP, it is a proprietary combination of ketoprofen, amytriptyline and oxymetazoline that is injected into standard arthroscopic irrigation solutions and perfused through the knee during surgery.

"Our analysis of the data does not demonstrate a lack of drug effect nor does it appear to undermine the viability of our phase III-ready OMS103HP programme for meniscectomy surgery," said Omeros Chairman and CEO Gregory A Demopulos. "As we learn more from our data analysis, we will provide additional information on our plans for OMS103HP."

An earlier phase I/II study of OMS103HP conducted at Stanford University in patients undergoing arthroscopic knee surgery for ACL reconstruction showed statistically significant improvement in postoperative knee range of motion and function, better pain management and earlier return to work, according to Omeros.

4th April 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics